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Your responsibility
The recommendations in this guideline represent the view of NICE, arrived at after careful
consideration of the evidence available. When exercising their judgement, professionals are
expected to take this guideline fully into account, alongside the individual needs, preferences and
values of their patients or service users. The application of the recommendations in this guideline
are not mandatory and the guideline does not override the responsibility of healthcare
professionals to make decisions appropriate to the circumstances of the individual patient, in
consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied
when individual health professionals and their patients or service users wish to use it. They should
do so in the context of local and national priorities for funding and developing services, and in light
of their duties to have due regard to the need to eliminate unlawful discrimination, to advance
equality of opportunity and to reduce health inequalities. Nothing in this guideline should be
interpreted in a way that would be inconsistent with compliance with those duties.
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This guideline should be read in conjunction with NG58.
Introduction
This guideline covers the assessment and management of adults and young people (aged 14 years
and older) who have a clinical diagnosis of psychosis with coexisting substance misuse.
The term psychosis is used to describe a group of severe mental health disorders characterised by
the presence of delusions and hallucinations that disrupt a person's perception, thoughts, emotions
and behaviour. The main forms of psychosis are schizophrenia (including schizoaffective disorder,
schizophreniform disorder and delusional disorder), bipolar disorder or other affective psychosis.
Substance misuse is a broad term encompassing, in this guideline, the harmful use of any
psychotropic substance, including alcohol and either legal or illicit drugs. Such use is usually, but not
always, regarded as a problem if there is evidence of dependence, characterised by psychological
reinforcement of repeated substance-taking behaviour and, in some cases, a withdrawal syndrome.
However, substance misuse can be harmful without dependence, especially among people with a
coexisting psychosis.
Approximately 40% of people with psychosis misuse substances at some point in their lifetime, at
least double the rate seen in the general population. In addition, people with coexisting substance
misuse have a higher risk of relapse and hospitalisation, and have higher levels of unmet needs
compared with other inpatients with psychosis who do not misuse substances.
Substance misuse among individuals with psychiatric disorders is associated with significantly
poorer outcomes than for individuals with a single disorder. These outcomes include worsening
psychiatric symptoms, poorer physical health, increased use of institutional services, poor
medication adherence, homelessness, increased risk of HIV infection, greater dropout from
services and higher overall treatment costs. Social outcomes are also significantly worse, including
greater homelessness and rooflessness[1], a higher impact on families and carers, and increased
contact with the criminal justice system.
People with psychosis commonly take various non-prescribed substances as a way of coping with
their symptoms, and in a third of people with psychosis, this amounts to harmful or dependent use.
The outcome for people with psychosis and coexisting substance misuse is worse than for people
without coexisting substance misuse, partly because the substances used may exacerbate the
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psychosis and partly because substances often interfere with pharmacological or psychological
treatment. This guideline aims to help healthcare professionals guide people with psychosis and
coexisting substance misuse to stabilise, reduce or stop their substance misuse, to improve
treatment adherence and outcomes, and to enhance their lives.
As well as primary and secondary services, this guideline also applies to services that are delivered
by the third sector and commissioned by the NHS.
[1] Rooflessness here refers to living rough or on the streets, whereas homelessness encompasses
people who are living in shelters.
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Person-centred care
This guideline offers best practice advice on the assessment and management of people with
psychosis and coexisting substance misuse.
Treatment and care should take into account people's needs and preferences. People with
psychosis and coexisting substance misuse should have the opportunity to make informed
decisions about their care and treatment, in partnership with their healthcare professionals. If
people do not have the capacity to make decisions, healthcare professionals should follow the
Department of Health's advice on consent and the code of practice that accompanies the Mental
Capacity Act. In Wales, healthcare professionals should follow advice on consent from the Welsh
Government.
Good communication between healthcare professionals and service users is essential. It should be
supported by evidence-based written information tailored to the person's needs. Treatment and
care, and the information people are given about it, should be culturally appropriate. It should also
be accessible to people with additional needs such as physical, sensory or learning disabilities, and
to people who do not speak or read English.
If the person agrees, families and carers should have the opportunity to be involved in decisions
about treatment and care. Families and carers should also be given the information and support
they need.
Care of young people in transition between child and adolescent mental health services (CAMHS),
and adult services should be planned and managed according to the best practice guidance
described in Transition: getting it right for young people.
Adult and CAMHS healthcare teams should work jointly to provide assessment and services to
young people with psychosis and coexisting substance misuse. Diagnosis and management should
be reviewed throughout the transition process, and there should be clarity about who is the lead
clinician to ensure continuity of care.
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Key priorities for implementation
Working with adults and young people with psychosis and coexisting substance misuse
When working with adults and young people with known or suspected psychosis and
coexisting substance misuse, take time to engage the person from the start, and build a
respectful, trusting, non-judgemental relationship in an atmosphere of hope and optimism. Be
direct in your communications, use a flexible and motivational approach, and take into account
that:
stigma and discrimination are associated with both psychosis and substance misuse
some people will try to conceal either one or both of their conditions
many people with psychosis and coexisting substance misuse fear being detained or
imprisoned, being given psychiatric medication forcibly or having their children taken
into care, and some fear that they may be 'mad'.
Recognition of psychosis with coexisting substance misuse in adults and young people
Healthcare professionals in all settings, including primary care, secondary care mental health
services, CAMHS and accident and emergency departments, and those in prisons and criminal
justice mental health liaison schemes, should routinely ask adults and young people with
known or suspected psychosis about their use of alcohol and/or prescribed and non-
prescribed (including illicit) drugs. If the person has used substances ask them about all of the
following:
particular substance(s) used
quantity, frequency and pattern of use
route of administration
duration of current level of use.
In addition, conduct an assessment of dependency (see Drug misuse: opioid detoxification [NICE
clinical guideline 52] and Alcohol use disorders: diagnosis, assessment and management of harmful
drinking and alcohol dependence [NICE clinical guideline 115]) and also seek corroborative
evidence from families, carers or significant others[2], where this is possible and permission is given.
Secondary care mental health services
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Competence
Healthcare professionals working within secondary care mental health services should ensure
they are competent in the recognition, treatment and care of adults and young people with
psychosis and coexisting substance misuse.
Pathways into care
Do not exclude adults and young people with psychosis and coexisting substance misuse from
age-appropriate mental healthcare because of their substance misuse.
Do not exclude adults and young people with psychosis and coexisting substance misuse from
age-appropriate substance misuse services because of a diagnosis of psychosis.
Coordinating care
Consider seeking specialist advice and initiating joint working arrangements with specialist
substance misuse services for adults and young people with psychosis being treated by
community mental health teams, and known to be:
severely dependent on alcohol or
dependent on both alcohol and benzodiazepines or
dependent on opioids and/or cocaine or crack cocaine.
Adult community mental health services or CAMHS should continue to provide care
coordination and treatment for the psychosis within joint working arrangements.
Substance misuse services
Competence
Healthcare professionals in substance misuse services should be competent to:
recognise the signs and symptoms of psychosis
undertake a mental health needs and risk assessment sufficient to know how and when
to refer to secondary care mental health services.
Inpatient mental health services
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Substance misuse
All inpatient mental health services should ensure that they have policies and procedures for
promoting a therapeutic environment free from drugs and alcohol that have been developed
together with service users and their families, carers or significant others[2]. These should
include: search procedures, visiting arrangements, planning and reviewing leave, drug and
alcohol testing, disposal of legal and illicit substances, and other security measures. Soon after
admission, provide all service users, and their families, carers or significant others[2], with
information about the policies and procedures.
Specific issues for young people with psychosis and coexisting substance misuse
Assessment and treatment
Those providing and commissioning services should ensure that:
age-appropriate mental health services are available for young people with psychosis
and coexisting substance misuse and
transition arrangements to adult mental health services are in place where appropriate.
[2] 'Significant other' refers not just to a partner but also to friends and any person the service user
considers to be important to them.
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1 Guidance
The following guidance is based on the best available evidence. The full guideline gives details of
the methods and the evidence used to develop the guidance.
1.1 Principles of care
Working with adults and young people with psychosis and coexisting substance misuse
1.1.1 When working with adults and young people with known or suspected
psychosis and coexisting substance misuse, take time to engage the person from
the start, and build a respectful, trusting, non-judgemental relationship in an
atmosphere of hope and optimism. Be direct in your communications, use a
flexible and motivational approach, and take into account that:
stigma and discrimination are associated with both psychosis and substance misuse
some people will try to conceal either one or both of their conditions
many people with psychosis and coexisting substance misuse fear being detained or
imprisoned, being given psychiatric medication forcibly or having their children taken
into care, and some fear that they may be 'mad'.
1.1.2 When working with adults and young people with known or suspected
psychosis and coexisting substance misuse:
ensure that discussions take place in settings in which confidentiality, privacy and
dignity can be maintained
avoid clinical language without adequate explanation
provide independent interpreters (who are not related to the person) if needed
aim to preserve continuity of care and minimise changes of key workers in order to
foster a therapeutic relationship.
Race and culture
1.1.3 Healthcare professionals working with adults and young people with psychosis
and coexisting substance misuse should ensure that they are competent to
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engage, assess, and negotiate with service users from diverse cultural and
ethnic backgrounds and their families, carers or significant others[3].
1.1.4 Work with local black and minority ethnic organisations and groups to help
support and engage adults and young people with psychosis and coexisting
substance misuse. Offer organisations and groups information and training
about how to recognise psychosis with coexisting substance misuse and access
treatment and care locally.
Providing information
1.1.5 Offer written and verbal information to adults and young people appropriate to
their level of understanding about the nature and treatment of both their
psychosis and substance misuse. Written information should:
include the Information for the public[4], which contains a list of organisations that can
provide more information (see section 5.3)
be available in the appropriate language or, for those who cannot use written text, in an
alternative format (audio or video).
1.1.6 All healthcare professionals in primary, secondary or specialist substance
misuse services working with adults and young people with psychosis should
offer information and advice about the risks associated with substance misuse
and the negative impact that it can have on the experience and management of
psychosis.
Working with and supporting families, carers and significant others[3]
1.1.7 Encourage families, carers or significant others[3] to be involved in the treatment
of adults and young people with psychosis and coexisting substance misuse to
help support treatment and care and promote recovery.
1.1.8 When families, carers or significant others[3] live or are in close contact with the
person with psychosis and coexisting substance misuse, offer family
intervention as recommended in Schizophrenia: core interventions in the
treatment and management of schizophrenia in adults in primary and secondary
care (NICE clinical guideline 82).
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1.1.9 When families, carers or significant others[3] are involved in supporting the
person with psychosis and coexisting substance misuse, discuss with them any
concerns about the impact of these conditions on them and on other family
members.
1.1.10 Offer families, carers or significant others[3] a carer's assessment of their caring,
physical, social, and mental health needs. Where needs are identified, develop a
care plan for the family member or carer.
1.1.11 Offer written and verbal information to families, carers or significant others[3]
appropriate to their level of understanding about the nature and treatment of
psychosis and substance misuse, including how they can help to support the
person. Written information should be available in the appropriate language or,
for those who cannot use written text, in an accessible format (audio or video).
1.1.12 Offer information to families, carers or significant others[3] about local family or
carer support groups and voluntary organisations, including those for psychosis
and for substance misuse, and help families, carers or significant others[3] to
access these.
1.1.13 Negotiate confidentiality and sharing of information between the person with
psychosis and coexisting substance misuse and their family, carer or a significant
other[3].
1.1.14 Ensure the needs of young carers or dependent adults of the person with
psychosis and coexisting substance misuse are assessed. Initiate safeguarding
procedures where appropriate (see recommendations 1.1.16–1.1.20).
Support for healthcare professionals
1.1.15 Working with people with psychosis and coexisting substance misuse can be
challenging and healthcare professionals should seek effective support – for
example, through professional supervision or staff support groups.
Safeguarding issues
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1.1.16 If people with psychosis and coexisting substance misuse are parents or carers
of children or young people, ensure that the child's or young person's needs are
assessed according to local safeguarding procedures[5].
1.1.17 If children or young people being cared for by people with psychosis and
coexisting substance misuse are referred to CAMHS under local safeguarding
procedures:
use a multi-agency approach, including social care and education, to ensure that
various perspectives on the child's life are considered
consider using the Common Assessment Framework[6]; advice on this can be sought
from the local named lead for safeguarding.
1.1.18 If serious concerns are identified, health or social care professionals working
with the child or young person (see recommendation 1.1.17) should develop a
child protection plan.
1.1.19 When working with people with psychosis and coexisting substance misuse who
are responsible for vulnerable adults, ensure that the home situation is risk
assessed and that safeguarding procedures are in place for the vulnerable adult.
Advice on safeguarding vulnerable adults can be sought from the local named
lead for safeguarding.
1.1.20 Consider adults with psychosis and coexisting substance misuse for assessment
according to local safeguarding procedures for vulnerable adults if there are
concerns regarding exploitation or self-care, or if they have been in contact with
the criminal justice system.
Consent, capacity and treatment decisions
1.1.21 Before undertaking any investigations for substance misuse, and before each
treatment decision is taken:
provide service users with full information appropriate to their needs about psychosis
and substance misuse and the management of both conditions, to ensure informed
consent
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understand and apply the principles underpinning the Mental Capacity Act (2005), and
be aware that mental capacity is decision-specific (that is, if there is doubt about
mental capacity, assessment of mental capacity should be made in relation to each
decision)
be able to assess mental capacity using the test set out in the Mental Capacity Act
(2005).
These principles should apply whether or not people are being detained or treated
under the Mental Health Act (1983; amended 1995 and 2007).
Advance decisions and statements
1.1.22 Develop advance decisions and advance statements in collaboration with adults
with psychosis and coexisting substance misuse, especially if their condition is
severe and they have been treated under the Mental Health Act (1983;
amended 1995 and 2007). Record the decisions and statements and include
copies in the care plan in primary and secondary care. Give copies to the person,
their care coordinator, and their family, carer or a significant other[3] if the
person agrees.
1.1.23 Take advance decisions and advance statements into account in accordance
with the Mental Capacity Act (2005). Although advance decisions and advance
statements can be overridden using the Mental Health Act (1983; amended
1995 and 2007), try to honour them wherever possible.
Working with the voluntary sector
1.1.24 Healthcare professionals in primary care and secondary care mental health
services, and in specialist substance misuse services, should work
collaboratively with voluntary sector organisations that provide help and
support for adults and young people with psychosis and coexisting substance
misuse. Ensure that advocates from such organisations are included in the care
planning and care programming process wherever this is possible and agreed by
the person with psychosis and coexisting substance misuse.
1.1.25 Healthcare professionals in primary care and secondary care mental health
services, and in specialist substance misuse services, should work
collaboratively with voluntary sector organisations providing services for adults
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and young people with psychosis and coexisting substance misuse to develop
agreed protocols for routine and crisis care.
1.2 Recognition of psychosis with coexisting substance misuse
1.2.1 Healthcare professionals in all settings, including primary care, secondary care
mental health services, CAMHS and accident and emergency departments, and
those in prisons and criminal justice mental health liaison schemes, should
routinely ask adults and young people with known or suspected psychosis about
their use of alcohol and/or prescribed and non-prescribed (including illicit)
drugs. If the person has used substances ask them about all of the following:
particular substance(s) used
quantity, frequency and pattern of use
route of administration
duration of current level of use.
In addition, conduct an assessment of dependency (see Drug misuse: opioid detoxification [NICE
clinical guideline 52] and Alcohol use disorders: diagnosis, assessment and management of harmful
drinking and alcohol dependence [NICE clinical guideline 115]) and also seek corroborative
evidence from families, carers or significant others[3], where this is possible and permission is given.
1.2.2 Healthcare professionals in all settings, including primary care, secondary care
mental health services, CAMHS and accident and emergency departments, and
those in prisons and criminal justice mental health liaison schemes, should
routinely assess adults and young people with known or suspected substance
misuse for possible psychosis. Seek corroborative evidence from families, carers
or significant others[3], where this is possible and permission is given.
1.3 Primary care
Referral from primary care
1.3.1 Refer all adults and young people with psychosis or suspected psychosis,
including those who are suspected of coexisting substance misuse, to either
secondary care mental health services or CAMHS for assessment and further
management.
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1.3.2 Refer all adults and young people with substance misuse or suspected
substance misuse who are suspected of having coexisting psychosis to
secondary care mental health services or CAMHS for assessment and further
management.
Physical healthcare
1.3.3 Monitor the physical health of adults and young people with psychosis and
coexisting substance misuse, as described in the guideline on schizophrenia
(NICE clinical guideline 82). Pay particular attention to the impact of alcohol and
drugs (prescribed and non-prescribed) on physical health. Monitoring should be
conducted at least once a year or more frequently if the person has a significant
physical illness or there is a risk of physical illness because of substance misuse.
1.4 Secondary care mental health services
Competence
1.4.1 Healthcare professionals working within secondary care mental health services
should ensure they are competent in the recognition, treatment and care of
adults and young people with psychosis and coexisting substance misuse.
1.4.2 Healthcare professionals working within secondary care mental health services
with adults and young people with psychosis and coexisting substance misuse
should consider having supervision, advice, consultation and/or training from
specialists in substance misuse services. This is to aid in the development and
implementation of treatment plans for substance misuse within CAMHS or
adult community mental health services.
Pathways into care
1.4.3 Do not exclude adults and young people with psychosis and coexisting
substance misuse from age-appropriate mental healthcare because of their
substance misuse.
1.4.4 Do not exclude adults and young people with psychosis and coexisting
substance misuse from age-appropriate substance misuse services because of a
diagnosis of psychosis.
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1.4.5 For most adults with psychosis and coexisting substance misuse, treatment for
both conditions should be provided by healthcare professionals in secondary
care mental health services such as community-based mental health teams.
Coordinating care
1.4.6 Consider seeking specialist advice and initiating joint working arrangements
with specialist substance misuse services for adults and young people with
psychosis being treated by community mental health teams, and known to be:
severely dependent on alcohol or
dependent on both alcohol and benzodiazepines or
dependent on opioids and/or cocaine or crack cocaine.
Adult community mental health services or CAMHS should continue to provide care
coordination and treatment for the psychosis within joint working arrangements.
1.4.7 Consider seeking specialist advice and initiate joint working arrangements with
specialist substance misuse services if the person's substance misuse:
is difficult to control and/or
leads to significant impairment of functioning, family breakdown or significant social
disruption such as homelessness.
1.4.8 If a person with psychosis and coexisting substance misuse requires planned
detoxification from either drugs or alcohol, this should take place in an inpatient
setting (see section 1.6).
1.4.9 Delivery of care and transfer between services for adults and young people with
psychosis and coexisting substance misuse should include a care coordinator
and use the Care Programme Approach.
Assessment
1.4.10 Adults and young people with psychosis and coexisting substance misuse
attending secondary care mental health services should be offered a
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comprehensive, multidisciplinary assessment, including assessment of all of the
following:
personal history
mental, physical and sexual health
social, family and economic situation
accommodation, including history of homelessness and stability of current living
arrangements
current and past substance misuse and its impact upon their life, health and response
to treatment
criminal justice history and current status
personal strengths and weaknesses and readiness to change their substance use
and other aspects of their lives.
The assessment may need to take place over several meetings to gain a full
understanding of the person and the range of problems they experience, and to
promote engagement.
1.4.11 When assessing adults and young people with psychosis and coexisting
substance misuse, seek corroborative evidence from families, carers or
significant others[3] where this is possible and permission is given. Summarise the
findings, share this with the person and record it in their care plan.
1.4.12 Review any changes in the person's use of substances. This should include
changes in:
the way the use of substances affects the person over time
patterns of use
mental and physical state
circumstances and treatment.
Share the summary with the person and record it in their care plan.
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1.4.13 When assessing adults and young people with psychosis and coexisting
substance misuse, be aware that low levels of substance use that would not
usually be considered harmful or problematic in people without psychosis, can
have a significant impact on the mental health of people with psychosis.
1.4.14 Regularly assess and monitor risk of harm to self and/or others and develop and
implement a risk management plan to be reviewed when the service users'
circumstances or levels of risk change. Specifically consider additional risks
associated with substance misuse, including:
physical health risks (for example, withdrawal seizures, delirium tremens, blood-borne
viruses, accidental overdose, and interactions with prescribed medication) and
the impact that substance use may have on other risks such as self-harm, suicide, self-
neglect, violence, abuse of or by others, exploitation, accidental injury and offending
behaviour.
Biological/physical testing
1.4.15 Biological or physical tests for substance use (such as blood and urine tests or
hair analysis) may be useful in the assessment, treatment and management of
substance misuse for adults and young people with psychosis. However, this
should be agreed with the person first as part of their care plan. Do not use
biological or physical tests in routine screening for substance misuse in adults
and young people with psychosis.
Treatment
1.4.16 Before starting treatment for adults and young people with psychosis and
coexisting substance misuse, review:
the diagnosis of psychosis and of the coexisting substance misuse, especially if either
diagnosis has been made during a crisis or emergency presentation and
the effectiveness of previous and current treatments and their acceptability to the
person; discontinue ineffective treatments.
1.4.17 When developing a care plan for an adult or young person with psychosis and
coexisting substance misuse, take account of the complex and individual
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relationships between substance misuse, psychotic symptoms, emotional state,
behaviour and the person's social context.
1.4.18 Ensure that adults and young people with psychosis and coexisting substance
misuse are offered evidence-based treatments for both conditions (see
recommendations 1.4.19 and 1.4.20).
1.4.19 For the treatment of psychosis, see Bipolar disorder: the management of bipolar
disorder in adults, children and adolescents, in primary and secondary care
(NICE clinical guideline 38) or the guideline on schizophrenia (NICE clinical
guideline 82).
1.4.20 For the treatment of substance misuse, see:
Alcohol-use disorders: diagnosis and clinical management of alcohol-related physical
complications and the guideline on alcohol dependence and harmful alcohol use (NICE
clinical guidelines 100 and CG115) and/or
Drug misuse: psychosocial interventions and the guideline on opioid detoxification
(NICE clinical guidelines 51 and 52).
1.4.21 When developing a treatment plan for a person with psychosis and coexisting
substance misuse, tailor the plan and the sequencing of treatments to the
person and take account of:
the relative severity of both the psychosis and the substance misuse at different times
and
the person's social and treatment context and
the person's readiness for change.
1.4.22 Do not exclude adults and young people with psychosis and coexisting
substance misuse from contingency management programmes because of their
psychosis.
1.4.23 Use antipsychotics according to the guideline on schizophrenia (NICE clinical
guideline 82) or bipolar disorder (NICE clinical guideline 38) because there is no
evidence for any differential benefit for one antipsychotic over another for
people with psychosis and coexisting substance misuse.
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1.4.24 Use depot/long-acting injectable antipsychotics according to the guideline on
schizophrenia (NICE clinical guideline 82) in managing covert non-adherence
with treatment for psychosis and not as a specific treatment for psychosis and
coexisting substance misuse.
1.4.25 When prescribing medication for adults and young people with psychosis and
coexisting substance misuse:
take into account the level and type of substance misuse, especially of alcohol, as this
may alter the metabolism of prescribed medication, decrease its effectiveness and/or
increase the risk of side effects
warn the person about potential interactions between substances of misuse and
prescribed medication
discuss the problems and potential dangers of using non-prescribed substances and
alcohol to counteract the effects or side effects of prescribed medication.
1.5 Substance misuse services
Competence
1.5.1 Healthcare professionals in substance misuse services should be competent to:
recognise the signs and symptoms of psychosis
undertake a mental health needs and risk assessment sufficient to know how and when
to refer to secondary care mental health services.
Assessment
1.5.2 Adults and young people with psychosis and coexisting substance misuse
attending substance misuse services should be offered a comprehensive,
multidisciplinary mental health assessment in addition to an assessment of their
substance misuse.
Joint working
1.5.3 Healthcare professionals in substance misuse services should be present at
Care Programme Approach meetings for adults and young people with
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psychosis and coexisting substance misuse within their service who are also
receiving treatment and support in other health services.
1.5.4 Specialist substance misuse services should provide advice, consultation, and
training for healthcare professionals in adult mental health services and
CAMHS regarding the assessment and treatment of substance misuse, and of
substance misuse with coexisting psychosis.
1.5.5 Specialist substance misuse services should work closely with secondary care
mental health services to develop local protocols derived from this guideline for
adults and young people with psychosis and coexisting substance misuse. The
agreed local protocols should set out responsibilities and processes for
assessment, referral, treatment and shared care across the whole care pathway.
1.6 Inpatient mental health services
Substance misuse
1.6.1 All inpatient mental health services should ensure that they have policies and
procedures for promoting a therapeutic environment free from drugs and
alcohol that have been developed together with service users and their families,
carers or significant others[3]. These should include: search procedures, visiting
arrangements, planning and reviewing leave, drug and alcohol testing, disposal
of legal and illicit substances, and other security measures. Soon after
admission, provide all service users, and their families, carers or significant
others[3], with information about the policies and procedures.
1.6.2 When carrying out a comprehensive assessment for all adults and young people
admitted to inpatient mental health services, ensure that they are assessed for
current substance misuse and evidence of withdrawal symptoms at the point of
admission.
1.6.3 Biological or physical tests for substance use should only be considered in
inpatient services as part of the assessment and treatment planning for adults
and young people with psychosis and coexisting substance misuse. Obtain
consent for these tests and inform the person of the results as part of an agreed
treatment plan. Where mental capacity is lacking, refer to the Mental Capacity
Act (2005).
Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in
healthcare settings (CG120)
© NICE 2011. All rights reserved. Page 23 of 41
1.6.4 Ensure that planned detoxification from either drugs or alcohol is undertaken
only:
with the involvement and advice of substance misuse services
in an inpatient setting, preferably in specialist detoxification units, or designated
detoxification beds within inpatient mental health services and
as part of an overall treatment plan.
For the further management of opioid detoxification see the guideline on opioid
detoxification (NICE clinical guideline 52). For the further management of assisted
alcohol withdrawal see the guideline on alcohol dependence and harmful alcohol use
(NICE clinical guideline 115).
Discharge
1.6.5 Do not discharge adults and young people with psychosis and coexisting
substance misuse from an inpatient mental health service solely because of
their substance misuse.
1.6.6 When adults and young people with psychosis and coexisting substance misuse
are discharged from an inpatient mental health service, ensure that they have:
an identified care coordinator and
a care plan that includes a consideration of needs associated with both their psychosis
and their substance misuse and
been informed of the risks of overdose if they start reusing substances, especially
opioids, that have been reduced or discontinued during the inpatient stay.
1.7 Staffed accommodation
Exclusion from services
1.7.1 Do not exclude people with psychosis and coexisting substance misuse from
staffed accommodation (such as supported or residential care) solely because of
their substance misuse
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1.7.2 Do not exclude people with psychosis and coexisting substance misuse from
staffed accommodation aimed at addressing substance misuse solely because of
their diagnosis of psychosis.
Aims of treatment
1.7.3 Ensure that people with psychosis and coexisting substance misuse who live in
staffed accommodation receive treatment for both their psychosis and their
substance misuse with the explicit aim of helping the person remain in stable
accommodation.
1.8 Specific issues for young people with psychosis and coexisting substance
misuse
Competence
1.8.1 Professionals in Tier 1 (primary care and educational settings) should be
competent to recognise early signs of psychosis and substance misuse in young
people.
1.8.2 Healthcare professionals in Tier 3 (community mental health teams) and Tier 4
(specialist inpatient and regional services) CAMHS, and in early intervention in
psychosis services, should be competent in the management of psychosis and
substance misuse in young people.
Identification and referral
1.8.3 Professionals in Tier 1 (primary care and educational settings) should seek
advice or consultation from Tier 2 CAMHS (primary care) when signs of
psychosis are detected in young people. If healthcare professionals in Tier 2
CAMHS detect signs of psychosis in young people, a referral to Tier 3 CAMHS
or early intervention in psychosis services for young people should be made
according to local protocols.
1.8.4 Ask all young people seen in Tier 3 and Tier 4 CAMHS and in early intervention
in psychosis services who have psychosis or suspected psychosis about
substance misuse (see recommendation 1.2.1).
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1.8.5 Children and young people who, after comprehensive assessment, are
considered to be at high risk of harm to themselves or others, should be referred
directly to Tier 4 CAMHS including inpatient services where necessary.
Assessment and treatment
1.8.6 Healthcare professionals working with young people with psychosis and
coexisting substance misuse should ensure they are familiar with the legal
framework that applies to young people including the Mental Health Act (1983;
amended 1995 and 2007), the Mental Capacity Act (2005), and the Children Act
(2004).
1.8.7 For psychological, psychosocial, family and medical interventions for young
people, follow the recommendations for adults in this guideline; they may need
to be adapted according to the young person's circumstances and age. In
addition, other agencies, including children's services, should be involved to
ensure that the young person's educational, employment, family and housing
needs are met.
1.8.8 When prescribing medication, take into account the young person's age and
weight when determining the dose. If it is appropriate to prescribe unlicensed
medication, explain to the young person and/or their parents or carers the
reasons for doing this.
1.8.9 Those providing and commissioning services should ensure that:
age-appropriate mental health services are available for young people with psychosis
and coexisting substance misuse and
transition arrangements to adult mental health services are in place where
appropriate.
[3] 'Significant other' refers not just to a partner but also to friends and any person the service user
considers to be important to them.
[4] Available in English and Welsh.
[5] Safeguarding Children.
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[6] Common Assessment Framework
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2 Notes on the scope of the guidance
NICE guidelines are developed in accordance with a scope that defines what the guideline will and
will not cover. The scope of this guideline is available.
How this guideline was developed
NICE commissioned the National Collaborating Centre for Mental Health to develop this guideline.
The Centre established a Guideline Development Group (see appendix A), which reviewed the
evidence and developed the recommendations. An independent guideline review panel oversaw
the development of the guideline (see appendix B).
There is more information about how NICE clinical guidelines are developed on the NICE website
and in How NICE clinical guidelines are developed: an overview for stakeholders, the public and the
NHS.
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3 Implementation
NICE has developed tools to help organisations implement this guidance.
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4 Research recommendations
The Guideline Development Group has made the following recommendations for research, based
on its review of evidence, to improve NICE guidance and patient care in the future. The Guideline
Development Group's full set of research recommendations is detailed in the full guideline.
4.1 Determining prevalence, risk and protective factors, and course of illness
What are the prevalence, risk and protective factors, and course of illness for different
combinations of psychosis and coexisting substance misuse (for example, schizophrenia and
cannabis misuse or bipolar disorder and alcohol misuse)?
Why this is important
Studies vary in terms of the definitions and diagnosis of psychosis and substance misuse, and how
they are conducted. This makes it difficult to draw conclusions about prevalence and patterns in
patient groups differentiated by diagnosis, ethnicity and other demographics. Additionally, most
studies are cross-sectional, so little is known about how both conditions change over time.
Moreover, there is little guidance about which levels and patterns of substance misuse in which
patient groups are associated with the worst clinical and social outcomes. Such information is
necessary to target resources at groups most at risk of very poor outcomes.
This question should be answered using a longitudinal study design with a representative sample
large enough to establish the prevalence, pattern, and epidemiology of different combinations of
psychosis and coexisting substance misuse, associated social determinants, treatment and
outcome. The study should also collect information that could inform the development of new
interventions or the modification of existing interventions to improve prognosis.
4.2 Predicting the onset of substance misuse in young people with psychosis
What risk factors predict the onset of substance misuse in young people with psychosis?
Why this is important
People with psychosis and coexisting substance misuse are more likely to be non-adherent to
prescribed medication, and have poor engagement with treatment programmes, increased risk of
suicide, more and longer inpatient stays, increased risk of violence and time spent in the criminal
justice system, and poorer overall prognosis. Because the onset of psychosis at a younger age is also
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an indicator of poor prognosis, people with a combination of younger age of onset and coexisting
substance misuse may have a particularly poor prognosis. A clearer understanding of the risk and
protective factors for substance misuse in young people with psychosis, and the interrelationship
of the two conditions over time, may facilitate the development of treatment approaches for the
coexisting conditions in this group. This may then improve the longer term outcome for a group of
people who tend to have a poor prognosis.
This question should be answered using a prospective cohort study design.
4.3 Psychosocial interventions versus standard care
Are psychosocial interventions clinically and cost effective when compared with standard care for
people with psychosis and coexisting substance misuse?
Why this is important
Psychosocial interventions are recommended for the treatment of substance misuse, with
contingency management showing particular promise. However, they have not been adequately
tested in people who also have psychosis.
This question should be answered using a randomised controlled trial that examines short- and
medium-term outcomes over at least 18 months. Studies should focus on people whose misuse of
substances is most often encountered in clinical practice and has the greatest impact on mental
health (such as cannabis and polysubstance misuse) and on those interventions – such as
contingency management, cognitive therapy and relapse prevention – that show most promise in
people with substance misuse without psychosis. Those providing the intervention should be
trained and supervised to ensure that the results are robust and generalisable. Outcomes should
reflect both observer and service user-rated assessments of improvement (including mental health
and social functioning) and the intervention's acceptability. Studies need to be large enough to
determine the intervention's costs and cost effectiveness.
4.4 Environmental interventions versus standard care
Are environmental interventions clinically and cost effective when compared with standard care
for people with psychosis and coexisting substance misuse?
Why this is important
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Social and other environmental factors can play a role in triggering and maintaining substance
misuse in people with psychosis, and in reducing the likelihood of progress and recovery. Evidence
suggests that when the primary focus of management involves improving the environment, both
conditions may improve.
This question should be answered using a randomised controlled trial that examines short- and
medium-term outcomes over at least 12 months. Studies should focus on people with psychosis
whose misuse of substances is most often encountered in clinical practice and has the greatest
impact on mental health (such as cannabis and polysubstance misuse), and on interventions that
take a collaborative approach to identifying and modifying social and environmental factors that
may trigger substance misuse. Those providing the intervention should be trained and supervised
to ensure that the results are robust and generalisable. Outcomes should reflect both observer and
service user-rated assessments of improvement (including mental health and social functioning)
and the intervention's acceptability. Studies need to be large enough to determine the
intervention's costs and cost effectiveness.
4.5 Clozapine versus other pharmacological interventions
Is clozapine clinically and cost effective when compared with other pharmacological interventions
for people with psychosis and coexisting substance misuse?
Why this is important
The NICE guideline on schizophrenia (NICE clinical guideline 82) states that clozapine should be
offered to people with schizophrenia whose illness has not responded adequately to treatment
despite the sequential use of adequate doses of at least two different antipsychotic drugs.
However, there is insufficient evidence to guide healthcare professionals about the use of clozapine
in people with psychosis and coexisting substance misuse. Expert opinion often advocates
clozapine as having a particular role in this population, but the evidence to support such statements
is lacking. Clozapine is expensive and has a wide range of side effects, some of which may be life-
threatening if not monitored correctly.
This question should be answered using a randomised controlled trial in which participants are
stratified for the presenting problem. It should report short- and longer-term outcomes (including
substance misuse, acceptability of the intervention, and cost effectiveness) of at least 12 months'
duration.
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5 Other versions of this guideline
5.1 Full guideline
The full guideline, Psychosis with coexisting substance misuse: assessment and management in
adults and young people, contains details of the methods and evidence used to develop the
guideline. It is published by the National Collaborating Centre for Mental Health.
5.2 Information for the public
NICE has produced information for the public explaining this guideline.
We encourage NHS and voluntary sector organisations to use text from this information in their
own materials about psychosis with coexisting substance misuse.
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7 Updating the guideline
NICE clinical guidelines are updated so that recommendations take into account important new
information. New evidence is checked 3 years after publication, and healthcare professionals and
patients are asked for their views; we use this information to decide whether all or part of a
guideline needs updating. If important new evidence is published at other times, we may decide to
do a more rapid update of some recommendations. Please see our website for information about
updating the guideline.
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Appendix B: The Guideline Review Panel
The Guideline Review Panel is an independent panel that oversees the development of the
guideline and takes responsibility for monitoring adherence to NICE guideline development
processes. In particular, the panel ensures that stakeholder comments have been adequately
considered and responded to. The panel includes members from the following perspectives:
primary care, secondary care, lay, public health and industry.
Dr Robert Walker (Chair)
General Practitioner, Workington
Mr Robin Beal
Consultant in Accident and Emergency Medicine, Isle of Wight
Dr Mark Hill
Head of Medical Affairs, Novartis Pharmaceuticals Ltd
Dr John Harley
Clinical Governance and Prescribing Lead and General Practitioner, North Tees PCT
Mrs Ailsa Donnelly
Lay member
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About this guideline
NICE clinical guidelines are recommendations about the treatment and care of people with specific
diseases and conditions in the NHS in England and Wales.
The guideline was developed by the National Collaborating Centre for Mental Health. The
Collaborating Centre worked with a group of healthcare professionals (including consultants, GPs
and nurses), patients and carers, and technical staff, who reviewed the evidence and drafted the
recommendations. The recommendations were finalised after public consultation.
The methods and processes for developing NICE clinical guidelines are described in The guidelines
manual.
We have produced information for the public explaining this guideline. Tools to help you put the
guideline into practice and information about the evidence it is based on are also available.
Changes after publication
January 2012: minor maintenance
January 2013: minor maintenance
February 2013: minor maintenance
Your responsibility
This guidance represents the view of NICE, which was arrived at after careful consideration of the
evidence available. Healthcare professionals are expected to take it fully into account when
exercising their clinical judgement. However, the guidance does not override the individual
responsibility of healthcare professionals to make decisions appropriate to the circumstances of
the individual patient, in consultation with the patient and/or guardian or carer, and informed by
the summary of product characteristics of any drugs they are considering.
Implementation of this guidance is the responsibility of local commissioners and/or providers.
Commissioners and providers are reminded that it is their responsibility to implement the
guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have
regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a
way that would be inconsistent with compliance with those duties.
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